drug · antibody
zanidatamab
pre_registrationupdated 3mo agoby $JAZZ Jazz Pharmaceuticals plc🔗 ChEMBL
community read0 votes
Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and biliary tract neoplasm and 4 investigational indications.
targets
Receptor tyrosine-protein kinase erbB-2
all catalysts(0)
nothing on the calendar yet
Trials studying zanidatamab
- phase2Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma
- phase2AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas
- phase3Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
- phase2Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- phase2A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
- phase2A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- phase3Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
- phase3A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
News(2)
- Biomarker-Directed Therapies Move the GI Oncology Paradigm Beyond a One-Size-Fits-All Approach: With Michael J. Pishvaian, MD, PhDMichael J. Pishvaian, MD, PhD discusses how biomarker-directed strategies, including HER2, CLDN18.2, and KRAS inhibition, are transforming GI cancer care.onclive · 3mo ago
- Approaching First-Line Treatment in PD-L1 CPS <1 HER2-Positive GEAZanidatamab’s dual HER2 binding shows striking single-agent activity in gastric and biliary cancers, hinting at synergy beyond pertuzumab-trastuzumab blockade.onclive · 3mo ago
Data sources
last refreshed 12m ago
Found something off?
comments(0)
5-min edit window · permanent after that